Durata Therapeutics Launches, Buys Virucon Pharma
Durata Therapeutics Inc., an antibiotic development platform recently formed by five venture capital firms, has acquired Vicuron Pharmaceuticals, developer of an antibiotic drug candidate called dalbavancin, from Pfizer. No financial terms were disclosed. Durata's backers are New Leaf Venture Partners, Domain Associates, Aisling Capital, Sofinnova Ventures and Canaan Partners.
21 December 2009•2 mins read
